<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="exd70134" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">Exp Dermatol</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">EXD</journal-id><journal-title-group><journal-title>Experimental Dermatology</journal-title></journal-title-group><issn pub-type="ppub">0906-6705</issn><issn pub-type="epub">1600-0625</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12210339</article-id><article-id pub-id-type="pmcid-ver">PMC12210339.1</article-id><article-id pub-id-type="pmcaid">12210339</article-id><article-id pub-id-type="pmcaiid">12210339</article-id><article-id pub-id-type="pmid">40590271</article-id><article-id pub-id-type="doi">10.1111/exd.70134</article-id><article-id pub-id-type="publisher-id">EXD70134</article-id><article-id pub-id-type="other">EXD-25-0107</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Incidence and Clinical Characteristics of Active Tuberculosis in Psoriasis Patients From a High&#8208;Burden Setting: An 18&#8208;Year Retrospective Study of 86 Patients</article-title></title-group><contrib-group><contrib id="exd70134-cr-0001" contrib-type="author"><name name-style="western"><surname>Trakanwittayarak</surname><given-names initials="S">Suphattra</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4911-7712</contrib-id><xref rid="exd70134-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="exd70134-cr-0002" contrib-type="author" corresp="yes"><name name-style="western"><surname>Chularojanamontri</surname><given-names initials="L">Leena</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6625-6445</contrib-id><xref rid="exd70134-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>leenajim@gmail.com</email></address></contrib><contrib id="exd70134-cr-0003" contrib-type="author"><name name-style="western"><surname>Chaiyabutr</surname><given-names initials="C">Chayada</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3161-5206</contrib-id><xref rid="exd70134-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="exd70134-cr-0004" contrib-type="author"><name name-style="western"><surname>Silpa&#8208;archa</surname><given-names initials="N">Narumol</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1678-5442</contrib-id><xref rid="exd70134-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="exd70134-cr-0005" contrib-type="author"><name name-style="western"><surname>Wongpraparut</surname><given-names initials="C">Chanisada</given-names></name><xref rid="exd70134-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="exd70134-cr-0006" contrib-type="author"><name name-style="western"><surname>Chiowchanwisawakit</surname><given-names initials="P">Praveena</given-names></name><xref rid="exd70134-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="exd70134-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Dermatology</named-content>
<institution>Faculty of Medicine Siriraj Hospital, Mahidol University</institution>
<city>Bangkok</city>
<country country="TH">Thailand</country>
</aff><aff id="exd70134-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Division of Rheumatology, Department of Medicine</named-content>
<institution>Faculty of Medicine Siriraj Hospital, Mahidol University</institution>
<city>Bangkok</city>
<country country="TH">Thailand</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Leena Chularojanamontri (<email>leenajim@gmail.com</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2025</year></pub-date><volume>34</volume><issue seq="50">7</issue><issue-id pub-id-type="pmc-issue-id">491859</issue-id><issue-id pub-id-type="doi">10.1111/exd.v34.7</issue-id><elocation-id>e70134</elocation-id><history><date date-type="rev-recd"><day>31</day><month>5</month><year>2025</year></date><date date-type="received"><day>07</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-04 05:25:27.940"><day>04</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Experimental Dermatology</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="EXD-34-e70134.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:EXD-34-e70134.pdf"/><abstract><title>ABSTRACT</title><p>Real&#8208;world data on concurrent psoriasis and active tuberculosis (TB) remain limited, particularly in high TB&#8208;burden settings. This retrospective study evaluated the incidence, prevalence, and clinical characteristics of psoriasis patients with active TB who had received topical or systemic treatments. Medical records from 13&#8201;066 psoriasis patients who presented at Siriraj Hospital over 18&#8201;years were reviewed. Among these, 86 (0.66%) developed active TB, yielding an incidence range of 135&#8211;1332 per 100&#8201;000 psoriasis patients. The mean patient age was 50.4&#8201;<bold>&#177;</bold>&#8201;15.7&#8201;years; 63 were men and 23 were women. Pulmonary TB occurred in 55 patients (64.0%), whereas 31 (36.0%) developed extrapulmonary TB. Male sex and smoking were associated with pulmonary TB. The most common pulmonary symptoms were chronic cough (65.5%) and dyspnoea (60.0%), although 7.3% were asymptomatic. Time to TB onset was shorter for extrapulmonary cases (5.7&#8201;<bold>&#177;</bold>&#8201;5.1&#8201;years) than for pulmonary cases (7.4&#8201;<bold>&#177;</bold>&#8201;6.5&#8201;years), but this difference was not statistically significant. Extrapulmonary disease most frequently involved the lymph node and pleura (25.8%) or the gastrointestinal tract (16.1%). Notably, all four patients who received infliximab within 1&#8201;year before TB diagnosis developed extrapulmonary TB. In conclusion, the incidence of TB in psoriasis patients in endemic regions may be high. Geographic factors, sex, smoking, and treatment history appear to influence TB risk. Close monitoring is critical, particularly in high&#8208;burden settings.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="exd70134-kwd-0001">calculated incidence rate</kwd><kwd id="exd70134-kwd-0002">endemic areas</kwd><kwd id="exd70134-kwd-0003">psoriasis</kwd><kwd id="exd70134-kwd-0004">tuberculosis</kwd></kwd-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="9"/><word-count count="5300"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>July 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.8 mode:remove_FC converted:03.07.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="exd70134-cit-1001"><string-name name-style="western"><given-names>S.</given-names><surname>Trakanwittayarak</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Chularojanamontri</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Chaiyabutr</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Silpa&#8208;archa</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Wongpraparut</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Chiowchanwisawakit</surname></string-name>, &#8220;<article-title>Incidence and Clinical Characteristics of Active Tuberculosis in Psoriasis Patients From a High&#8208;Burden Setting: An 18&#8208;Year Retrospective Study of 86 Patients</article-title>,&#8221; <source>Experimental Dermatology</source><volume>34</volume>, no. <issue>7</issue> (<year>2025</year>): <elocation-id>e70134</elocation-id>, <pub-id pub-id-type="doi">10.1111/exd.70134</pub-id>.<pub-id pub-id-type="pmid">40590271</pub-id><pub-id pub-id-type="pmcid">PMC12210339</pub-id></mixed-citation>
</p><fn-group id="exd70134-ntgp-0001"><fn fn-type="funding" id="exd70134-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn></fn-group></notes></front><body id="exd70134-body-0001"><sec id="exd70134-sec-0001"><label>1</label><title>Introduction</title><p>Tuberculosis (TB), an infection caused by <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Mycobacterium tuberculosis</italic>
</styled-content>, remains a major cause of morbidity and mortality worldwide, despite being preventable and treatable&#160;[<xref rid="exd70134-bib-0001" ref-type="bibr">1</xref>]. According to a recent World Health Organisation report, TB rates rose by 3.6% in 2021, from 10.1 million cases in 2020 to 10.6 million cases&#160;[<xref rid="exd70134-bib-0002" ref-type="bibr">2</xref>]. The majority of incident TB occurs in Southeast Asia, Africa, and the Western Pacific [<xref rid="exd70134-bib-0003" ref-type="bibr">3</xref>]. In 2021, Thailand remained among the 14 countries with the highest TB burden [<xref rid="exd70134-bib-0001" ref-type="bibr">1</xref>].</p><p>Psoriasis is a prevalent chronic inflammatory dermatosis that can involve the skin and joints, primarily driven by aberrant immune cell activation. It remains unclear whether these immune disturbances affect anti&#8208;TB defences. A previous study found that patients with severe psoriasis in a TB&#8208;endemic region exhibit diminished central memory T&#8208;cell responses to TB [<xref rid="exd70134-bib-0004" ref-type="bibr">4</xref>]. In a nationwide cohort study from Taiwan, psoriasis conferred a higher TB risk compared with the general population [<xref rid="exd70134-bib-0005" ref-type="bibr">5</xref>]. Data remain limited and inconsistent regarding the link between traditional systemic antipsoriatic agents and TB risk. According to the National Health Insurance Research Database of Taiwan, one investigation reported no significant association [<xref rid="exd70134-bib-0005" ref-type="bibr">5</xref>], whereas another identified methotrexate as a risk factor [<xref rid="exd70134-bib-0006" ref-type="bibr">6</xref>]. However, the risk is well established among those receiving tumour necrosis factor (TNF) antagonists [<xref rid="exd70134-bib-0007" ref-type="bibr">7</xref>, <xref rid="exd70134-bib-0008" ref-type="bibr">8</xref>, <xref rid="exd70134-bib-0009" ref-type="bibr">9</xref>].</p><p>This study aimed to determine the calculated incidence rate, prevalence, and clinical characteristics of active TB in psoriasis patients from a TB&#8208;endemic region (Thailand) who had received topical or systemic therapy.</p></sec><sec sec-type="methods" id="exd70134-sec-0002"><label>2</label><title>Methods</title><p>This study was approved by the Siriraj Institutional Review Board of the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (Certificate of Approval: Si&#8208;831/2022). We searched our center's database from 2005 through 2022 using the International Statistical Classification of Diseases, Tenth Revision. Adult patients with psoriasis or psoriatic arthritis were identified by codes L40.0&#8211;L40.9, and patients with pulmonary or extrapulmonary TB were identified by codes A15&#8211;A19. We then retrospectively reviewed the medical records of these patients.</p><p>Psoriasis was diagnosed by experienced dermatologists. TB was diagnosed by infectious disease specialists or pulmonologists based on clinicalfindings presentations and supporting investigations, including chest X&#8208;ray (CXR), smear and culture for acid&#8208;fast bacilli, tissue biopsy, tuberculin skin test (TST) or interferon&#8208;&#947; release assays (IGRA). We excluded patients who had TB before developing psoriasis, as well as those with incomplete medical records, including incomplete TB work&#8208;up or lack of treatment at Siriraj Hospital. Consequently, 86 patients with psoriasis who developed active TB after psoriasis treatment were enrolled. We collected demographic data (including age at psoriasis and TB onset), comorbidities, treatments, laboratory findings, radiological results, and details of psoriasis and TB therapies.</p><p>Baseline characteristics of all patients were compared using independent <italic toggle="yes">t</italic>&#8208;tests for continuous variables (expressed as mean&#8201;&#177;&#8201;standard deviation) and Chi&#8208;square test and/or Fisher's exact test for categorical variables (expressed as number and percentage). Odds ratios were calculated to assess the degree of association, with 95% confidence intervals (95% CI). Statistical significance was set at a <italic toggle="yes">p</italic> value of less than 0.05. All statistical analyses were performed using IBM SPSS Statistics for Windows, Version 29.0 (IBM Corp., Armonk, NY).</p></sec><sec sec-type="results" id="exd70134-sec-0003"><label>3</label><title>Results</title><sec id="exd70134-sec-0004"><label>3.1</label><title>All Active <styled-content style="fixed-case" toggle="no">TB</styled-content> in Patients With Psoriasis</title><sec id="exd70134-sec-0005"><label>3.1.1</label><title>Incidence and Patient Characteristics</title><p>Figure&#160;<xref rid="exd70134-fig-0001" ref-type="fig">1</xref> presents the yearly incidence rate of TB per 100&#8201;000 psoriasis patients from 2005 to 2022, ranging from 135 to 1332 per 100&#8201;000. During this 18&#8208;year interval, 86 of the 13&#8201;066 patients with psoriasis developed TB, corresponding to a prevalence of 0.66%. Of these 86 individuals, 63 were male (73.3%) and 23 were female (26.7%), with a mean age of 50.4&#8201;<bold>&#177;</bold>&#8201;15.7&#8201;years (Table&#160;<xref rid="exd70134-tbl-0001" ref-type="table">1</xref>). The most common comorbidities were hypertension (59.3%), dyslipidaemia (40.7%), and diabetes mellitus (39.5%). Thirteen patients (15.1%) had concomitant psoriatic arthritis. The mean duration to TB onset following psoriasis treatment initiation was 6.8&#8201;<bold>&#177;</bold>&#8201;6.1&#8201;years. During the entire study period, 53 patients (61.6%) received only topical treatments, whereas 33 received systemic therapies.</p><fig position="float" fig-type="FIGURE" id="exd70134-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Annual incidence rate of tuberculosis among psoriasis patients per 100&#8201;000 from 2005 to 2022.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="EXD-34-e70134-g001.jpg"/></fig><table-wrap position="float" id="exd70134-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Comparison of patient characteristics between pulmonary and extrapulmonary tuberculosis cases including odds ratios (OR) and their corresponding 95% confidence intervals (95% CI).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Characteristics</th><th align="center" rowspan="2" valign="bottom" colspan="1">Total (<italic toggle="yes">n</italic>&#8201;=&#8201;86)</th><th align="center" colspan="4" valign="bottom" rowspan="1">Active TB (<italic toggle="yes">n</italic>&#8201;=&#8201;86)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Pulmonary TB (<italic toggle="yes">n</italic>&#8201;=&#8201;55)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Extrapulmonary TB (<italic toggle="yes">n</italic>&#8201;=&#8201;31)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Female, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (26.7)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (18.2)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (41.9)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">63 (73.3)</td><td align="center" valign="top" rowspan="1" colspan="1">45 (81.8)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (58.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.017<xref rid="exd70134-note-0007" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">3.25 (1.21, 8.87)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years; mean&#8201;&#177;&#8201;SD)</td><td align="center" valign="top" rowspan="1" colspan="1">50.4&#8201;&#177;&#8201;15.7</td><td align="center" valign="top" rowspan="1" colspan="1">52.3&#8201;&#177;&#8201;15.3</td><td align="center" valign="top" rowspan="1" colspan="1">46.4&#8201;&#177;&#8201;15.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.081</td><td align="center" valign="top" rowspan="1" colspan="1">1.03 (0.99, 1.06)</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">Comorbid diseases<xref rid="exd70134-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="top" rowspan="1" colspan="1">51 (59.3)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (61.8)</td><td align="center" valign="top" rowspan="1" colspan="1">17 (54.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.527</td><td align="center" valign="top" rowspan="1" colspan="1">1.33 (0.55, 3.25)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Dyslipidemia</td><td align="center" valign="top" rowspan="1" colspan="1">35 (40.7)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (40.0)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (41.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.861</td><td align="center" valign="top" rowspan="1" colspan="1">0.92 (0.38, 2.26)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" valign="top" rowspan="1" colspan="1">34 (39.5)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (41.8)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (35.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.564</td><td align="center" valign="top" rowspan="1" colspan="1">1.31 (0.53, 3.25)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Liver diseases</td><td align="center" valign="top" rowspan="1" colspan="1">11 (12.8)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (10.9)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (16.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.515</td><td align="center" valign="top" rowspan="1" colspan="1">0.64 (0.18, 2.29)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Chronic kidney disease</td><td align="center" valign="top" rowspan="1" colspan="1">11 (12.8)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (14.5)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (9.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.739</td><td align="center" valign="top" rowspan="1" colspan="1">1.59 (0.39, 6.49)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Human immunodeficiency virus infection</td><td align="center" valign="top" rowspan="1" colspan="1">9 (10.5)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (9.1)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (12.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.717</td><td align="center" valign="top" rowspan="1" colspan="1">0.68 (0.17, 2.73)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Malignancy</td><td align="center" valign="top" rowspan="1" colspan="1">8 (9.3)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (10.9)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.705</td><td align="center" valign="top" rowspan="1" colspan="1">1.78 (0.34, 9.39)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Autoimmune diseases<xref rid="exd70134-note-0005" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">5 (5.8)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (5.5)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td><td align="center" valign="top" rowspan="1" colspan="1">0.84 (0.13,5.30)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (27.9)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (38.2)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (9.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.005<xref rid="exd70134-note-0007" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">5.77 (1.56, 21.35)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alcohol consumption, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (15.1)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (18.2)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (9.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.361</td><td align="center" valign="top" rowspan="1" colspan="1">2.07 (0.53, 8.19)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Close contact with active TB patients, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (7.0)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (5.5)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (9.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.663</td><td align="center" valign="top" rowspan="1" colspan="1">0.54 (0.10, 2.85)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Time to TB development after psoriasis diagnosis (years; mean&#8201;&#177;&#8201;SD)</td><td align="center" valign="top" rowspan="1" colspan="1">6.8&#8201;&#177;&#8201;6.1</td><td align="center" valign="top" rowspan="1" colspan="1">7.4&#8201;&#177;&#8201;6.5</td><td align="center" valign="top" rowspan="1" colspan="1">5.7&#8201;&#177;&#8201;5.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.207</td><td align="center" valign="top" rowspan="1" colspan="1">1.05 (0.97, 1.14)</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">Previous immunosuppressive treatments within 1&#8201;year before a diagnosis of active TB</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Methotrexate alone, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (15.1)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (20.0)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.122</td><td align="center" valign="top" rowspan="1" colspan="1">1.88 (0.55, 6.44)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cyclosporine alone, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Infliximab alone, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.360</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Methotrexate + infliximab, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.127</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Azathioprine<xref rid="exd70134-note-0006" ref-type="table-fn">
<sup>c</sup>
</xref>&#8201;+&#8201;infliximab, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.360</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Infliximab alone or with other drugs</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0/12</td><td align="center" valign="top" rowspan="1" colspan="1">4/6</td><td align="center" valign="top" rowspan="1" colspan="1">0.005<xref rid="exd70134-note-0007" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr></tbody></table><table-wrap-foot id="exd70134-ntgp-0002"><fn id="exd70134-note-0002"><p>
<italic toggle="yes">Note:</italic> Pulmonary TB&#8201;=&#8201;disease (case), Extrapulmonary TB&#8201;=&#8201;control. OR of age: 1&#8201;year increase determine increase 1.03 times of pulmonary TB. OR of time to TB development after psoriasis diagnosis: 1&#8201;year increase determine increase 1.05 times of pulmonary TB.</p></fn><fn id="exd70134-note-0003"><p>Abbreviations: SD, standard deviation; TB, tuberculosis.</p></fn><fn id="exd70134-note-0004"><label>
<sup>a</sup>
</label><p>A patient could have more than one comorbid disease.</p></fn><fn id="exd70134-note-0005"><label>
<sup>b</sup>
</label><p>Autoimmune diseases included systemic lupus erythematosus, systemic sclerosis, and pemphigus vulgaris.</p></fn><fn id="exd70134-note-0006"><label>
<sup>c</sup>
</label><p>Azathioprine was prescribed for a patient with psoriatic arthritis.</p></fn><fn id="exd70134-note-0007"><label>*</label><p>
<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="exd70134-sec-0006"><label>3.1.2</label><title>Pulmonary vs. Extrapulmonary <styled-content style="fixed-case" toggle="no">TB</styled-content>
</title><p>Among the 86 patients, 55 (64.0%) had pulmonary TB and 31 (36.0%) had extrapulmonary TB. Male sex (<italic toggle="yes">p</italic>&#8201;=&#8201;0.017) and smoking (<italic toggle="yes">p</italic>&#8201;=&#8201;0.005) were significantly associated with pulmonary TB. The odds of pulmonary TB were higher among males and smokers, with odds ratios of 3.25 (95% CI: 1.21&#8211;8.87) and 5.77 (95% CI: 1.56&#8211;21.35), respectively, compared to extrapulmonary TB. Comorbidities that could weaken the immune system did not appear to increase the risk of extrapulmonary TB. All nine patients with concomitant human immunodeficiency virus (HIV) infection were male. Among these HIV&#8208;positive patients, four had moderate to severe psoriasis affecting more than 10% of their body surface area. Two received acitretin, and the other two received only topical treatments. Six HIV&#8208;positive patients (66.7%) had CD4 counts below 100 cells/mm<sup>3</sup> (range, 1&#8211;90 cells/mm<sup>3</sup>), whereas three (33.3%) had CD4 counts above 200 cells/mm<sup>3</sup> (range, 225&#8211;238 cells/mm<sup>3</sup>). The time to TB onset was shorter in patients with extrapulmonary disease (5.7&#8201;<bold>&#177;</bold>&#8201;5.1&#8201;years) than in those with pulmonary disease (7.4&#8201;<bold>&#177;</bold>&#8201;6.5&#8201;years), although the difference was not statistically significant. Table&#160;<xref rid="exd70134-tbl-0002" ref-type="table">2</xref> presents data on patients included in our study who received biologic therapies during the study period. The administered biologic agents included anti&#8208;TNF therapies&#8212;etanercept (42.9%) and infliximab (57.1%) &#8211; as well as ustekinumab (14.3%), an IL&#8208;12/23 inhibitor. Notably, one patient received ustekinumab and, after discontinuing it for 2&#8201;years, was subsequently treated with infliximab. Etanercept had been discontinued for at least 3&#8201;years for all three patients prior to the onset of TB, whereas infliximab was the only anti&#8208;TNF agent administered within 1 year preceding TB development. All patients who received infliximab within 1&#8201;year before their TB diagnosis developed extrapulmonary rather than pulmonary TB.</p><table-wrap position="float" id="exd70134-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Clinical characteristics of the patients exposed to biological drugs in our study (<italic toggle="no">N</italic>&#8201;=&#8201;7).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="bottom" rowspan="1" colspan="1">Patient 1</th><th align="center" valign="bottom" rowspan="1" colspan="1">Patient 2</th><th align="center" valign="bottom" rowspan="1" colspan="1">Patient 3</th><th align="center" valign="bottom" rowspan="1" colspan="1">Patient 4</th><th align="center" valign="bottom" rowspan="1" colspan="1">Patient 5</th><th align="center" valign="bottom" rowspan="1" colspan="1">Patient 6</th><th align="center" valign="bottom" rowspan="1" colspan="1">Patient 7</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at tuberculosis (TB) diagnosis (years)</td><td align="center" valign="top" rowspan="1" colspan="1">71</td><td align="center" valign="top" rowspan="1" colspan="1">46</td><td align="center" valign="top" rowspan="1" colspan="1">69</td><td align="center" valign="top" rowspan="1" colspan="1">57</td><td align="center" valign="top" rowspan="1" colspan="1">51</td><td align="center" valign="top" rowspan="1" colspan="1">60</td><td align="center" valign="top" rowspan="1" colspan="1">67</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender</td><td align="center" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">Male</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Psoriatic arthritis</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Biologic therapy (date/month/year)</td><td align="center" valign="top" rowspan="1" colspan="1">Etanercept (22/03/2007&#8211;22/03/2009)</td><td align="center" valign="top" rowspan="1" colspan="1">Infliximab (17/03/2010&#8211;08/12/2010)</td><td align="center" valign="top" rowspan="1" colspan="1">Etanercept (15/01/2008&#8211;03/05/2010)</td><td align="center" valign="top" rowspan="1" colspan="1">Infliximab (11/01/2017&#8211;20/04/2017)</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Infliximab (04/05/2009)</p>
<p>Ustekinumab (07/12/2011&#8211;09/02/2012)</p>
<p>Infliximab (07/05/2014&#8211;01/09/2021)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Etanercept (09/11/2006&#8211;19/09/2007)</td><td align="center" valign="top" rowspan="1" colspan="1">Infliximab (28/09/2012&#8211;31/10/2016, 04/05/2017&#8211;07/12/2021)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Biologic therapy within 1&#8201;year before TB onset</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">Infliximab</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">Infliximab</td><td align="center" valign="top" rowspan="1" colspan="1">Infliximab</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">Infliximab</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Concomitant systemic treatment within 1&#8201;year before TB onset</td><td align="center" valign="top" rowspan="1" colspan="1">Methotrexate</td><td align="center" valign="top" rowspan="1" colspan="1">Azathioprine</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">Methotrexate</td><td align="center" valign="top" rowspan="1" colspan="1">Methotrexate</td><td align="center" valign="top" rowspan="1" colspan="1">Acitretin</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Date of TB diagnosis (date/month/year)</td><td align="center" valign="top" rowspan="1" colspan="1">18/12/2012</td><td align="center" valign="top" rowspan="1" colspan="1">21/04/2011</td><td align="center" valign="top" rowspan="1" colspan="1">04/03/2020</td><td align="center" valign="top" rowspan="1" colspan="1">14/06/2017</td><td align="center" valign="top" rowspan="1" colspan="1">04/10/2021</td><td align="center" valign="top" rowspan="1" colspan="1">04/01/2011</td><td align="center" valign="top" rowspan="1" colspan="1">31/01/2017</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Site of TB</td><td align="center" valign="top" rowspan="1" colspan="1">Pulmonary</td><td align="center" valign="top" rowspan="1" colspan="1">Pleura</td><td align="center" valign="top" rowspan="1" colspan="1">Pleura</td><td align="center" valign="top" rowspan="1" colspan="1">Peritonitis</td><td align="center" valign="top" rowspan="1" colspan="1">Peritonitis</td><td align="center" valign="top" rowspan="1" colspan="1">Synovitis</td><td align="center" valign="top" rowspan="1" colspan="1">Pleura</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diagnostic method</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Clinical</p>
<p>Abnormal CXR</p>
<p>CT chest</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Clinical</p>
<p>Abnormal CXR</p>
<p>Light criteria</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Clinical</p>
<p>Abnormal CXR</p>
<p>Light criteria</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Clinical</p>
<p>Culture positive</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Clinical</p>
<p>AFB positive</p>
<p>Culture positive</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Clinical</p>
<p>Tissue biopsy</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Clinical</p>
<p>Tissue biopsy</p>
<p>AFB positive</p>
<p>Culture positive</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TB culture</td><td align="center" valign="top" rowspan="1" colspan="1">No growth</td><td align="center" valign="top" rowspan="1" colspan="1">No growth</td><td align="center" valign="top" rowspan="1" colspan="1">Not done</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">
<styled-content style="fixed-case" toggle="no">M. tuberculosis</styled-content> complex</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">
<styled-content style="fixed-case" toggle="no">M. tuberculosis</styled-content> complex</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">
<styled-content style="fixed-case" toggle="no">M. tuberculosis</styled-content> complex</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">
<styled-content style="fixed-case" toggle="no">M. tuberculosis</styled-content> complex</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Recurrence</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">Yes (30/12/2021)</td></tr></tbody></table><table-wrap-foot id="exd70134-ntgp-0003"><fn id="exd70134-note-0008"><p>Abbreviations: AFB, acid fast bacilli; CT, compute tomography; CXR, chest X&#8208;ray; TB, tuberculosis.</p></fn></table-wrap-foot></table-wrap></sec><sec id="exd70134-sec-0007"><label>3.1.3</label><title>Recurrent <styled-content style="fixed-case" toggle="no">TB</styled-content>
</title><p>Two patients experienced recurrent TB infection in the same organ (one pleural and one pulmonary) within 6&#8201;years of their initial diagnosis. The mean time to recurrence was 5.4&#8201;<bold>&#177;</bold>&#8201;0.7&#8201;years (range, 4.9&#8211;5.9&#8201;years). One patient developed a second TB episode while receiving infliximab therapy, whereas the other had no history of immunosuppressive treatment at recurrence.</p></sec></sec><sec id="exd70134-sec-0008"><label>3.2</label><title>Pulmonary <styled-content style="fixed-case" toggle="no">TB</styled-content> in Patients With Psoriasis</title><sec id="exd70134-sec-0009"><label>3.2.1</label><title>Clinical Presentation</title><p>Figure&#160;<xref rid="exd70134-fig-0002" ref-type="fig">2</xref> illustrates the diagnostic details of pulmonary TB in this cohort. Most patients (92.7%) presented with symptoms, with chronic cough (65.5%) as the most common complaint. Dyspnea (60.0%), fever (45.5%), and weight loss (41.8%) were also frequent, while haemoptysis (10.9%) was the least common symptom.</p><fig position="float" fig-type="FIGURE" id="exd70134-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Diagnostic methods for pulmonary tuberculosis in this study. CT, computed tomography; IGRA, interferon gamma releasing assay.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="EXD-34-e70134-g003.jpg"/></fig></sec><sec id="exd70134-sec-0010"><label>3.2.2</label><title>Radiographic Findings</title><p>Among the symptomatic patients, 48 (94.1%) had abnormal CXR findings. These included pulmonary infiltrations in 42 patients, cavities in three patients, infiltration with pleural effusion in two patients, and isolated pleural effusion in one patient. All four asymptomatic patients had abnormal CXR detected during routine check&#8208;ups, which revealed nodules and masses.</p></sec></sec><sec id="exd70134-sec-0011"><label>3.3</label><title>Extrapulmonary <styled-content style="fixed-case" toggle="no">TB</styled-content> in Patients With Psoriasis</title><sec id="exd70134-sec-0012"><label>3.3.1</label><title>Distribution and Clinical Presentation</title><p>Table&#160;<xref rid="exd70134-tbl-0003" ref-type="table">3</xref> shows that tuberculous lymphadenitis and TB pleura (25.8% each) were the most common forms of extrapulmonary TB, followed by gastrointestinal TB (16.1%). All patients with TB lymphadenitis presented with lymphadenopathy. Organ&#8208;specific symptoms were the most frequent clinical manifestations of extrapulmonary TB. Patients with genitourinary tract, skin, and eye involvement often lacked fever. Even when test results were negative, some patients were diagnosed based on their history, clinical presentation, and exclusion of other possible causes.</p><table-wrap position="float" id="exd70134-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Clinical presentation, diagnostic methods, and laboratory findings in patients with extrapulmonary tuberculosis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Organs (<italic toggle="yes">n</italic>, %)</th><th align="center" rowspan="2" valign="bottom" colspan="1">Clinical manifestations</th><th align="center" colspan="2" valign="bottom" rowspan="1">Investigations</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Specimens</th><th align="center" valign="bottom" rowspan="1" colspan="1">Results</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Lymph node (<italic toggle="yes">n</italic>&#8201;=&#8201;8, 25.8)</td><td align="center" valign="top" rowspan="1" colspan="1">
<list list-type="simple" id="exd70134-list-0001"><list-item id="exd70134-li-0001"><label>&#8211;</label><p>Lymphadenopathy (<italic toggle="yes">n</italic>&#8201;=&#8201;8)</p></list-item><list-item id="exd70134-li-0002"><label>&#8211;</label><p>Fever (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item><list-item id="exd70134-li-0003"><label>&#8211;</label><p>Weight loss (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item></list>
</td><td align="center" valign="top" rowspan="1" colspan="1">Lymph node biopsy (<italic toggle="yes">n</italic>&#8201;=&#8201;8)</td><td align="center" valign="top" rowspan="1" colspan="1">
<list list-type="simple" id="exd70134-list-0002"><list-item id="exd70134-li-0004"><label>&#8211;</label><p>Smear &#8722;ve but culture +ve (<italic toggle="yes">n</italic>&#8201;=&#8201;4)</p></list-item><list-item id="exd70134-li-0005"><label>&#8211;</label><p>Smear and culture +ve (<italic toggle="yes">n</italic>&#8201;=&#8201;2)</p></list-item><list-item id="exd70134-li-0006"><label>&#8211;</label><p>Smear and culture &#8722;ve (<italic toggle="yes">n</italic>&#8201;=&#8201;2)</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pleura (<italic toggle="yes">n</italic>&#8201;=&#8201;8, 25.8)</td><td align="center" valign="top" rowspan="1" colspan="1">
<list list-type="simple" id="exd70134-list-0003"><list-item id="exd70134-li-0007"><label>&#8211;</label><p>Dyspnea (<italic toggle="yes">n</italic>&#8201;=&#8201;6)</p></list-item><list-item id="exd70134-li-0008"><label>&#8211;</label><p>Cough (<italic toggle="yes">n</italic>&#8201;=&#8201;6)</p></list-item><list-item id="exd70134-li-0009"><label>&#8211;</label><p>Fever (<italic toggle="yes">n</italic>&#8201;=&#8201;4)</p></list-item><list-item id="exd70134-li-0010"><label>&#8211;</label><p>Weight loss (<italic toggle="yes">n</italic>&#8201;=&#8201;3)</p></list-item></list>
</td><td align="center" valign="top" rowspan="1" colspan="1">Abnormal chest X ray, pleural fluid (<italic toggle="yes">n</italic>&#8201;=&#8201;7)</td><td align="center" valign="top" rowspan="1" colspan="1">
<list list-type="simple" id="exd70134-list-0004"><list-item id="exd70134-li-0011"><label>&#8211;</label><p>Pleural fluid profile +ve (<italic toggle="yes">n</italic>&#8201;=&#8201;5)</p></list-item><list-item id="exd70134-li-0012"><label>&#8211;</label><p>Smear &#8722;ve but culture +ve (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item><list-item id="exd70134-li-0013"><label>&#8211;</label><p>Smear and culture &#8722;ve (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Normal chest X ray, pleural tissue (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td><td align="center" valign="top" rowspan="1" colspan="1">Smear and culture +ve (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gastrointestinal (<italic toggle="yes">n</italic>&#8201;=&#8201;5, 16.1)</td><td align="center" valign="top" rowspan="1" colspan="1">
<list list-type="simple" id="exd70134-list-0005"><list-item id="exd70134-li-0014"><label>&#8211;</label><p>Weight loss (<italic toggle="yes">n</italic>&#8201;=&#8201;2)</p></list-item><list-item id="exd70134-li-0015"><label>&#8211;</label><p>Abdominal distension (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item><list-item id="exd70134-li-0016"><label>&#8211;</label><p>Ascites (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item><list-item id="exd70134-li-0017"><label>&#8211;</label><p>Fever (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item><list-item id="exd70134-li-0018"><label>&#8211;</label><p>Mass (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item></list>
</td><td align="center" valign="top" rowspan="1" colspan="1">Tissue biopsy (<italic toggle="yes">n</italic>&#8201;=&#8201;3)</td><td align="center" valign="top" rowspan="1" colspan="1">
<list list-type="simple" id="exd70134-list-0006"><list-item id="exd70134-li-0019"><label>&#8211;</label><p>Smear and culture +ve (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item><list-item id="exd70134-li-0020"><label>&#8211;</label><p>Smear and culture &#8722;ve (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item><list-item id="exd70134-li-0021"><label>&#8211;</label><p>Culture +ve (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Peritoneal fluid (<italic toggle="yes">n</italic>&#8201;=&#8201;2)</td><td align="center" valign="top" rowspan="1" colspan="1">
<list list-type="simple" id="exd70134-list-0007"><list-item id="exd70134-li-0022"><label>&#8211;</label><p>Smear and culture +ve (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item><list-item id="exd70134-li-0023"><label>&#8211;</label><p>Smear &#8722;ve but culture +ve (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item></list>
</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Musculoskeletal (<italic toggle="yes">n</italic>&#8201;=&#8201;4, 12.9)</td><td align="center" rowspan="2" valign="top" colspan="1">
<list list-type="simple" id="exd70134-list-0008"><list-item id="exd70134-li-0024"><label>&#8211;</label><p>Arthralgia (<italic toggle="yes">n</italic>&#8201;=&#8201;2)</p></list-item><list-item id="exd70134-li-0025"><label>&#8211;</label><p>Fever (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item><list-item id="exd70134-li-0026"><label>&#8211;</label><p>Mass (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item></list>
</td><td align="center" valign="top" rowspan="1" colspan="1">Tissue biopsy (<italic toggle="yes">n</italic>&#8201;=&#8201;3)</td><td align="center" valign="top" rowspan="1" colspan="1">
<list list-type="simple" id="exd70134-list-0009"><list-item id="exd70134-li-0027"><label>&#8211;</label><p>Smear and culture &#8722;ve (<italic toggle="yes">n</italic>&#8201;=&#8201;2)</p></list-item><list-item id="exd70134-li-0028"><label>&#8211;</label><p>Smear &#8722;ve but culture +ve (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item></list>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Synovial fluid (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td><td align="center" valign="top" rowspan="1" colspan="1">Smear and culture +ve (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Central nervous system (<italic toggle="yes">n</italic>&#8201;=&#8201;2, 6.5)</td><td align="center" valign="top" rowspan="1" colspan="1">
<list list-type="simple" id="exd70134-list-0010"><list-item id="exd70134-li-0029"><label>&#8211;</label><p>Headache (<italic toggle="yes">n</italic>&#8201;=&#8201;2)</p></list-item><list-item id="exd70134-li-0030"><label>&#8211;</label><p>Fever (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</p></list-item></list>
</td><td align="center" valign="top" rowspan="1" colspan="1">Cerebrospinal fluid (<italic toggle="yes">n</italic>&#8201;=&#8201;2)</td><td align="center" valign="top" rowspan="1" colspan="1">Cerebrospinal fluid profile +ve (<italic toggle="yes">n</italic>&#8201;=&#8201;2)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Genitourinary (<italic toggle="yes">n</italic>&#8201;=&#8201;2, 6.5)</td><td align="center" valign="top" rowspan="1" colspan="1">Persistent hematuria (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td><td align="center" valign="top" rowspan="1" colspan="1">Urine (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td><td align="center" valign="top" rowspan="1" colspan="1">Smear and culture &#8722;ve (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Overactive bladder (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td><td align="center" valign="top" rowspan="1" colspan="1">Tissue biopsy (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td><td align="center" valign="top" rowspan="1" colspan="1">PCR TB&#8201;+&#8201;ve (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Skin (<italic toggle="yes">n</italic>&#8201;=&#8201;1, 3.2)</td><td align="center" valign="top" rowspan="1" colspan="1">Mass (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td><td align="center" valign="top" rowspan="1" colspan="1">Tissue biopsy (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td><td align="center" valign="top" rowspan="1" colspan="1">Smear and culture +ve (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Eye (<italic toggle="yes">n</italic>&#8201;=&#8201;1, 3.2)</td><td align="center" valign="top" rowspan="1" colspan="1">Visual loss (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td><td align="center" valign="top" rowspan="1" colspan="1">Tissue biopsy, blood sample for IGRA (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td><td align="center" valign="top" rowspan="1" colspan="1">Smear and culture &#8722;ve but IGRA +ve (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td></tr></tbody></table><table-wrap-foot id="exd70134-ntgp-0004"><fn id="exd70134-note-0009"><p>
<italic toggle="yes">Note:</italic> A patient could have more than one symptom.</p></fn><fn id="exd70134-note-0010"><p>Abbreviations: +ve, positive; &#8722;ve, negative; IGRA, interferon gamma releasing assay; PCR, polymerase chain reaction; TB, tuberculosis.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="exd70134-sec-0013"><label>3.4</label><title>Management After <styled-content style="fixed-case" toggle="no">TB</styled-content> Diagnosis</title><sec id="exd70134-sec-0014"><label>3.4.1</label><title>Adjustments in Psoriasis Therapy</title><p>Following TB diagnosis, treatment regimens were modified in 15 patients. Nearly all patients discontinued systemic immunosuppressive treatments. Only two patients with severe psoriasis and psoriatic arthritis continued methotrexate, but their dosage was reduced.</p><p>Five of these patients experienced psoriasis progression within 2 months of the treatment modifications. Among them, two were transitioned from infliximab to topical corticosteroids, two from methotrexate to topical corticosteroids, and one had a reduced methotrexate dosage from three to two tablets per week. In contrast, the remaining 10 patients remained clinically stable. Of these, six receiving methotrexate and one receiving infliximab were switched to topical corticosteroids; one patient on methotrexate and another on infliximab were switched to acitretin; and in one patient, the methotrexate dosage was reduced from three to two tablets per week.</p></sec><sec id="exd70134-sec-0015"><label>3.4.2</label><title>Adverse Reactions to Anti&#8208;<styled-content style="fixed-case" toggle="no">TB</styled-content> Drugs</title><p>The most common side effects of anti&#8208;TB medications were gastrointestinal disturbances. Elevated liver enzymes, pruritus, nausea and vomiting, and cholestasis were observed in 7, 6, 4, and 1 patients, respectively. Six patients had drug allergies, which included minor maculopapular rashes in five patients and a severe drug reaction with eosinophilia and systemic symptoms in one patient. Drug rechallenge was successfully performed for minor rashes. In contrast, the patient with drug reaction with eosinophilia and systemic symptoms discontinued the offending drug (ethambutol) and extended treatment duration.</p></sec></sec></sec><sec sec-type="discussion" id="exd70134-sec-0016"><label>4</label><title>Discussion</title><p>As of 2022, the World Health Organisation estimated that the TB incidence among the Thai general population was 155 cases per 100&#8201;000 people [<xref rid="exd70134-bib-0002" ref-type="bibr">2</xref>, <xref rid="exd70134-bib-0010" ref-type="bibr">10</xref>]. The incidence rate was higher in males than in females and was most common in people aged 65&#8201;years or older. A study among healthcare workers, who may be asymptomatic, indicated that the average TB incidence in Thailand was 164 per 100&#8201;000 healthcare workers [<xref rid="exd70134-bib-0011" ref-type="bibr">11</xref>]. Our study showed that the TB incidence among 100&#8201;000 patients with psoriasis in 2022 was 898, which was nearly six times higher than that of the general population and healthcare workers. Chronic inflammation in psoriasis, which may impair the immune response to <styled-content style="fixed-case" toggle="no">
<italic toggle="no">M. tuberculosis</italic>
</styled-content>, combined with decreased immune function from psoriasis treatments and skin barrier dysfunction, may contribute to this increased incidence [<xref rid="exd70134-bib-0006" ref-type="bibr">6</xref>, <xref rid="exd70134-bib-0012" ref-type="bibr">12</xref>, <xref rid="exd70134-bib-0013" ref-type="bibr">13</xref>, <xref rid="exd70134-bib-0014" ref-type="bibr">14</xref>]. Additionally, more frequent and rigorous TB screening among psoriasis patients, particularly those receiving systemic or biologic therapies, may lead to higher detection rates compared to healthcare workers [<xref rid="exd70134-bib-0015" ref-type="bibr">15</xref>, <xref rid="exd70134-bib-0016" ref-type="bibr">16</xref>].</p><p>Aging, malnutrition, diabetes, smoking, alcohol use, and immunocompromised conditions can elevate the risk or progression of TB disease [<xref rid="exd70134-bib-0010" ref-type="bibr">10</xref>, <xref rid="exd70134-bib-0017" ref-type="bibr">17</xref>, <xref rid="exd70134-bib-0018" ref-type="bibr">18</xref>, <xref rid="exd70134-bib-0019" ref-type="bibr">19</xref>]. Among the 86 patients who developed active TB, the proportion who smoked or consumed alcohol was about two to four times higher than among those with a history of close contact with TB. Numerous studies, including meta&#8208;analyses, have shown that both active and passive smoking are independent risk factors for TB [<xref rid="exd70134-bib-0020" ref-type="bibr">20</xref>]. Smoking&#8208;related TB pathogenesis involves ciliary dysfunction, defects in the immune response of macrophages, and reduced production of TNF, all of which promote TB development [<xref rid="exd70134-bib-0021" ref-type="bibr">21</xref>]. Alcohol consumption increases pulmonary oxidative stress, impairing pulmonary innate immunity and alveolar macrophage phagocytosis [<xref rid="exd70134-bib-0022" ref-type="bibr">22</xref>]. Therefore, smoking and alcohol cessation not only improve psoriasis severity but also help prevent TB infection in patients with psoriasis, especially in TB&#8208;endemic areas [<xref rid="exd70134-bib-0023" ref-type="bibr">23</xref>, <xref rid="exd70134-bib-0024" ref-type="bibr">24</xref>].</p><p>All patients who developed TB while receiving biologic agents were on anti&#8208;TNFs rather than on interleukin (IL)&#8208;17 inhibitors or IL&#8208;23 inhibitors. Anti&#8208;TNFs (infliximab and etanercept) have been available in Thailand since 2010, whereas IL&#8208;17 antagonists and an IL&#8208;23 inhibitor (guselkumab) became available in 2017 and 2019, respectively. Given this timeline, there may be limited long&#8208;term data on the TB risk associated with IL&#8208;17 and IL&#8208;23 inhibitors, particularly in TB&#8208;endemic regions such as Thailand. However, current evidence indicates that anti&#8208;TNF agents pose a more clearly established risk of TB reactivation. Since newer IL&#8208;17 and IL&#8208;23 inhibitors may not substantially impair the immune response to TB, they could present a lower risk for TB reactivation, although vigilant surveillance and continued monitoring remain essential [<xref rid="exd70134-bib-0025" ref-type="bibr">25</xref>].</p><p>Janus kinase (JAK) inhibitors, such as tofacitinib (JAK1 and JAK3 inhibitor), upapacitinib (JAK1 inhibitor), deucravacitinib (TYK2 inhibitor), and brepocitinib (JAK1 and TYK2 inhibitor) have gained attention for their role in treating psoriasis and psoriatic arthritis [<xref rid="exd70134-bib-0026" ref-type="bibr">26</xref>, <xref rid="exd70134-bib-0027" ref-type="bibr">27</xref>]. JAK inhibitors interfere with the JAK&#8211;STAT signalling pathway, resulting in the inhibition of proinflammatory cytokine&#8208;mediated gene transcription. Among JAK inhibitors, tofacitinib has the most extensive clinical data available. Winthrop et&#160;al. evaluated the risk of TB in 5671 patients with rheumatoid arthritis receiving tofacitinib. It was shown that the risk of TB reactivation was influenced by baseline endemicity, with 21 of the 26 reported cases occurring in patients from highly endemic regions [<xref rid="exd70134-bib-0028" ref-type="bibr">28</xref>]. As the American College of Rheumatology guidelines recommend considering the risk of TB associated with tofacitinib comparable to that of anti&#8208;TNF agents, JAK inhibitors may be classified as high&#8208;risk drugs for TB reactivation [<xref rid="exd70134-bib-0029" ref-type="bibr">29</xref>].</p><p>Our study showed that chronic cough with dyspnea is an important indicator of pulmonary TB, whereas organ&#8208;specific symptoms suggest extrapulmonary TB. Furthermore, some patients may develop TB without apparent symptoms [<xref rid="exd70134-bib-0030" ref-type="bibr">30</xref>]. In endemic areas, routine screening and rigorous monitoring are therefore vital for early detection, even when obvious clinical manifestations are absent. Based on our findings and a review of the literature, we propose a screening and monitoring algorithm tailored to high&#8208;burden and resource&#8208;limited countries as illustrated in Figure&#160;<xref rid="exd70134-fig-0003" ref-type="fig">3</xref> [<xref rid="exd70134-bib-0031" ref-type="bibr">31</xref>, <xref rid="exd70134-bib-0032" ref-type="bibr">32</xref>, <xref rid="exd70134-bib-0033" ref-type="bibr">33</xref>, <xref rid="exd70134-bib-0034" ref-type="bibr">34</xref>]. Latent tuberculosis infection (LTBI) refers to the presence of infection without clinical symptoms, radiological abnormalities, and microbiological evidence of active disease [<xref rid="exd70134-bib-0033" ref-type="bibr">33</xref>]. Although there is no gold standard for its diagnosis, the World Health Organisation guideline recommends assessing the host's immune response using the TST or IGRA [<xref rid="exd70134-bib-0035" ref-type="bibr">35</xref>]. LTBI is typically identified by a positive TST or IGRA in the absence of symptoms and with a normal CXR. Patients with LTBI should receive at least 4&#8201;weeks of prophylactic treatment before initiating biologic agents and oral small molecules [<xref rid="exd70134-bib-0033" ref-type="bibr">33</xref>, <xref rid="exd70134-bib-0036" ref-type="bibr">36</xref>, <xref rid="exd70134-bib-0037" ref-type="bibr">37</xref>] especially anti&#8208;TNF agents and JAK inhibitors, which are associated with a high risk of TB reactivation [<xref rid="exd70134-bib-0033" ref-type="bibr">33</xref>, <xref rid="exd70134-bib-0034" ref-type="bibr">34</xref>, <xref rid="exd70134-bib-0036" ref-type="bibr">36</xref>]. Several studies have shown that IL&#8208;17 and IL&#8208;23 inhibitors do not appear to increase the risk of TB reactivation [<xref rid="exd70134-bib-0034" ref-type="bibr">34</xref>, <xref rid="exd70134-bib-0038" ref-type="bibr">38</xref>, <xref rid="exd70134-bib-0039" ref-type="bibr">39</xref>]. Some experts also recommend waiving TB prophylaxis in LTBI patients at high risk of complications, such as those with liver disease or previous intolerance to TB medications, when starting IL&#8208;17 or IL&#8208;23 inhibitors [<xref rid="exd70134-bib-0034" ref-type="bibr">34</xref>]. In patients with equivocal results from CXR or immunological tests (TST or IGRA), computed tomography may be used to differentiate between LTBI and active TB.</p><fig position="float" fig-type="FIGURE" id="exd70134-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>A proposed algorithm for tuberculosis (TB) screening and monitoring in endemic and resource&#8208;limited countries. CT, computed tomography; IGRA, interferon gamma releasing assay; IL, interleukin; JAK, janus kinase; LTBI, Latent Tuberculous Infection; TB, tuberculosis; TNF, tumour necrosis factor; TST, tuberculin skin test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="EXD-34-e70134-g002.jpg"/></fig><p>The limitations of this study include its single&#8208;centre, retrospective design and the relatively small sample size of included patients. A strength of the study, however, was the long&#8208;term follow&#8208;up of patients who developed TB while receiving systemic therapy for psoriasis. Further research, including case&#8211;control studies, would provide deeper insights.</p></sec><sec sec-type="conclusions" id="exd70134-sec-0017"><label>5</label><title>Conclusions</title><p>Compared with the general population, the incidence rate of TB among psoriasis patients appears higher in endemic regions. Several factors&#8212;including geographic region, sex, smoking, and specific treatment regimens&#8212;affect TB infection in this population. Monitoring and routine check&#8208;ups are essential for timely detection and management, especially in TB&#8208;endemic areas.</p></sec><sec id="exd70134-sec-0018"><title>Author Contributions</title><p>L.C. and S.T. designed the study. L.C., S.T., C.C., N.S., and C.W. collected the data. S.T., L.C., and P.C. wrote the paper with input from all the authors. All the authors read and approved the final manuscript.</p></sec><sec id="exd70134-sec-0020"><title>Ethics Statement</title><p>This study was approved by the Siriraj Institutional Review Board of the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (reference: Si&#8208;831/2020).</p></sec><sec sec-type="COI-statement" id="exd70134-sec-0021"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack id="exd70134-sec-0019"><title>Acknowledgements</title><p>The authors gratefully acknowledge Mr. Suthipol Udompunturak for his assistance with the statistical analysis, and Associate Professor Supparerk Disayabutr for his expert opinion on tuberculosis screening and monitoring. This was an unfunded study.</p></ack><sec sec-type="data-availability" id="exd70134-sec-0023"><title>Data Availability Statement</title><p>The data that support the findings of this study are available upon request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.</p></sec><ref-list content-type="cited-references" id="exd70134-bibl-0001"><title>References</title><ref id="exd70134-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="exd70134-cit-0001"><string-name name-style="western"><given-names>N.</given-names><surname>Chumpa</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Kawkitinarong</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wongpiyabovorn</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Paitoonpong</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Suwanpimolkul</surname></string-name>, &#8220;<article-title>Prevalence of Latent Tuberculosis Infection Among Pre&#8208;Clinical and Clinical Medical Students Using QuantiFERON&#8208;TB Gold Plus and Tuberculin Skin Test at a Teaching Hospital in Thailand: A Cross&#8208;Sectional Study</article-title>,&#8221; <source>Journal of Infection and Public Health</source><volume>15</volume> (<year>2022</year>): <fpage>400</fpage>&#8211;<lpage>405</lpage>.<pub-id pub-id-type="pmid">35325687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jiph.2022.02.010</pub-id></mixed-citation></ref><ref id="exd70134-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="exd70134-cit-0002"><string-name name-style="western"><given-names>S.</given-names><surname>Bagcchi</surname></string-name>, &#8220;<article-title>WHO'S Global Tuberculosis Report 2022</article-title>,&#8221; <source>Lancet Microbe</source><volume>4</volume> (<year>2023</year>): <elocation-id>e20</elocation-id>.<pub-id pub-id-type="pmid">36521512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-5247(22)00359-7</pub-id></mixed-citation></ref><ref id="exd70134-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="exd70134-cit-0003"><string-name name-style="western"><given-names>J.</given-names><surname>Chakaya</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Khan</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Ntoumi</surname></string-name>, et&#160;al., &#8220;<article-title>Global Tuberculosis Report 2020 &#8208; Reflections on the Global TB Burden, Treatment and Prevention Efforts</article-title>,&#8221; <source>International Journal of Infectious Diseases</source><volume>113</volume>, no. <issue>Suppl 1</issue> (<year>2021</year>): <fpage>S7</fpage>&#8211;<lpage>S12</lpage>.<pub-id pub-id-type="pmid">33716195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2021.02.107</pub-id><pub-id pub-id-type="pmcid">PMC8433257</pub-id></mixed-citation></ref><ref id="exd70134-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="exd70134-cit-0004"><string-name name-style="western"><given-names>L. C.</given-names><surname>Silva</surname></string-name>, <string-name name-style="western"><given-names>G. G.</given-names><surname>Silveira</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Arnone</surname></string-name>, et&#160;al., &#8220;<article-title>Decrease in <italic toggle="yes">Mycobacterium tuberculosis</italic> Specific Immune Responses in Patients With Untreated Psoriasis Living in a Tuberculosis Endemic Area</article-title>,&#8221; <source>Archives of Dermatological Research</source><volume>302</volume> (<year>2010</year>): <fpage>255</fpage>&#8211;<lpage>262</lpage>.<pub-id pub-id-type="pmid">19609541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00403-009-0982-2</pub-id></mixed-citation></ref><ref id="exd70134-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="exd70134-cit-0005"><string-name name-style="western"><given-names>Y. J.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>C. Y.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>J. L.</given-names><surname>Shen</surname></string-name>, <string-name name-style="western"><given-names>T. T.</given-names><surname>Chen</surname></string-name>, and <string-name name-style="western"><given-names>Y. T.</given-names><surname>Chang</surname></string-name>, &#8220;<article-title>Association Between Traditional Systemic Antipsoriatic Drugs and Tuberculosis Risk in Patients With Psoriasis With or Without Psoriatic Arthritis: Results of a Nationwide Cohort Study From Taiwan</article-title>,&#8221; <source>Journal of the American Academy of Dermatology</source><volume>69</volume> (<year>2013</year>): <fpage>25</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">23375515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2012.12.966</pub-id></mixed-citation></ref><ref id="exd70134-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="exd70134-cit-0006"><string-name name-style="western"><given-names>S. W.</given-names><surname>Ting</surname></string-name>, <string-name name-style="western"><given-names>S. Y.</given-names><surname>Ting</surname></string-name>, <string-name name-style="western"><given-names>Y. S.</given-names><surname>Lin</surname></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Lin</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Kuo</surname></string-name>, &#8220;<article-title>Association Between Different Systemic Therapies and the Risk of Tuberculosis in Psoriasis Patients: A Population&#8208;Based Study</article-title>,&#8221; <source>International Journal of Clinical Practice</source><volume>75</volume> (<year>2021</year>): <elocation-id>e15006</elocation-id>.<pub-id pub-id-type="pmid">34773345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijcp.15006</pub-id></mixed-citation></ref><ref id="exd70134-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="exd70134-cit-0007"><string-name name-style="western"><given-names>C.</given-names><surname>Solovan</surname></string-name> and <string-name name-style="western"><given-names>E.</given-names><surname>Chiticariu</surname></string-name>, &#8220;<article-title>Psoriasis, Anti&#8208;Tumor Necrosis Factor Therapy, and Tuberculosis: Report of Three Challenging Cases and Literature Review</article-title>,&#8221; <source>Infectious Disease and Therapy</source><volume>2</volume> (<year>2013</year>): <fpage>59</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40121-013-0003-9</pub-id><pub-id pub-id-type="pmcid">PMC4108098</pub-id><pub-id pub-id-type="pmid">25135824</pub-id></mixed-citation></ref><ref id="exd70134-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="exd70134-cit-0008"><string-name name-style="western"><given-names>S.</given-names><surname>Sarkar</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Panda</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>S. K.</given-names><surname>Raychaudhuri</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Ghosh</surname></string-name>, and <string-name name-style="western"><given-names>S. P.</given-names><surname>Raychaudhuri</surname></string-name>, &#8220;<article-title>Risk of Tuberculosis With Anti&#8208;Tumor Necrosis Factor&#8208;Alpha Therapy in Patients With Psoriasis and Psoriatic Arthritis in Indian Population</article-title>,&#8221; <source>Indian Journal of Dermatology, Venereology and Leprology</source><volume>86</volume> (<year>2020</year>): <fpage>1</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">31719235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijdvl.IJDVL_791_18</pub-id></mixed-citation></ref><ref id="exd70134-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="exd70134-cit-0009"><string-name name-style="western"><given-names>T.</given-names><surname>Ergun</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Seckin</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Baskan Bulbul</surname></string-name>, et&#160;al., &#8220;<article-title>The Risk of Tuberculosis in Patients With Psoriasis Treated With Anti&#8208;Tumor Necrosis Factor Agents</article-title>,&#8221; <source>International Journal of Dermatology</source><volume>54</volume> (<year>2015</year>): <fpage>594</fpage>&#8211;<lpage>599</lpage>.<pub-id pub-id-type="pmid">25753908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijd.12628</pub-id></mixed-citation></ref><ref id="exd70134-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="exd70134-cit-0010"><string-name name-style="western"><given-names>D.</given-names><surname>Goletti</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Meintjes</surname></string-name>, <string-name name-style="western"><given-names>B. B.</given-names><surname>Andrade</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Zumla</surname></string-name>, and <string-name name-style="western"><given-names>L. S.</given-names><surname>Shan</surname></string-name>, &#8220;<article-title>Insights From the 2024 WHO Global Tuberculosis Report &#8211; More Comprehensive Action, Innovation, and Investments Required for Achieving WHO End TB Goals</article-title>,&#8221; <source>International Journal of Infectious Diseases</source><volume>150</volume> (<year>2024</year>): <elocation-id>107325</elocation-id>.<pub-id pub-id-type="pmid">39631498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2024.107325</pub-id></mixed-citation></ref><ref id="exd70134-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="exd70134-cit-0011"><string-name name-style="western"><given-names>P.</given-names><surname>Mingchay</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Paitoonpong</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Kawkitinarong</surname></string-name>, <string-name name-style="western"><given-names>P. J.</given-names><surname>Ohata</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Suwanpimolkul</surname></string-name>, &#8220;<article-title>Tuberculosis at a University Hospital, Thailand: A Surprising Incidence of TB Among a New Generation of Highly Exposed Health Care Workers Who May Be Asymptomatic</article-title>,&#8221; <source>PLoS One</source><volume>17</volume> (<year>2022</year>): <elocation-id>e0273027</elocation-id>.<pub-id pub-id-type="pmid">36001595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0273027</pub-id><pub-id pub-id-type="pmcid">PMC9401166</pub-id></mixed-citation></ref><ref id="exd70134-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="exd70134-cit-0012"><string-name name-style="western"><given-names>T.</given-names><surname>Torres</surname></string-name>, <string-name name-style="western"><given-names>N. C.</given-names><surname>Brembilla</surname></string-name>, <string-name name-style="western"><given-names>R. G.</given-names><surname>Langley</surname></string-name>, et&#160;al., &#8220;<article-title>Treatment of Psoriasis With Biologic and Non&#8208;Biologic Targeted Therapies in Patients With Latent Tuberculosis Infection or at Risk for Tuberculosis Disease Progression: Recommendations From a SPIN&#8208;FRT Expert Consensus</article-title>,&#8221; <source>Journal of the European Academy of Dermatology and Venereology</source><volume>39</volume> (<year>2024</year>): <fpage>52</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="pmid">39149807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.20287</pub-id></mixed-citation></ref><ref id="exd70134-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="exd70134-cit-0013"><string-name name-style="western"><given-names>Y. A.</given-names><surname>Cho</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Ahn</surname></string-name>, <string-name name-style="western"><given-names>J. Y.</given-names><surname>Hong</surname></string-name>, et&#160;al., &#8220;<article-title>Serious Infections and Tuberculosis in Psoriasis Patients Receiving Systemic Therapy in Korea: A Nationwide Population&#8208;Based Cohort Study</article-title>,&#8221; <source>European Journal of Dermatology</source><volume>33</volume> (<year>2023</year>): <fpage>287</fpage>&#8211;<lpage>295</lpage>.<pub-id pub-id-type="pmid">37594337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1684/ejd.2023.4500</pub-id></mixed-citation></ref><ref id="exd70134-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="exd70134-cit-0014"><string-name name-style="western"><given-names>J. G. M.</given-names><surname>Bergboer</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Zeeuwen</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Schalkwijk</surname></string-name>, &#8220;<article-title>Genetics of Psoriasis: Evidence for Epistatic Interaction Between Skin Barrier Abnormalities and Immune Deviation</article-title>,&#8221; <source>Journal of Investigative Dermatology</source><volume>132</volume> (<year>2012</year>): <fpage>2320</fpage>&#8211;<lpage>2331</lpage>.<pub-id pub-id-type="pmid">22622420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jid.2012.167</pub-id></mixed-citation></ref><ref id="exd70134-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="exd70134-cit-0015"><string-name name-style="western"><given-names>S.</given-names><surname>Pradhan</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Madke</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Neema</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Kabra</surname></string-name>, <string-name name-style="western"><given-names>A. L.</given-names><surname>Singh</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Yadav</surname></string-name>, &#8220;<article-title>Screening of Latent Tuberculous Infection (LTBI) Before Starting Anti&#8208;Tumor Necrosis Factor Therapy in Patients With Psoriasis: A Primer for Clinical Dermatologist</article-title>,&#8221; <source>Indian Journal of Dermatology</source><volume>66</volume> (<year>2021</year>): <fpage>501</fpage>&#8211;<lpage>507</lpage>.<pub-id pub-id-type="pmid">35068505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijd.IJD_649_16</pub-id><pub-id pub-id-type="pmcid">PMC8751712</pub-id></mixed-citation></ref><ref id="exd70134-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="exd70134-cit-0016"><string-name name-style="western"><given-names>B.</given-names><surname>Vest</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Buhnerkempe</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Minielly</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Larson</surname></string-name>, &#8220;<article-title>Utility of Tuberculosis Screening in Psoriasis Patients Treated With Biologics and Traditional Immunosuppressant Medications: Experience at a Single US Institution</article-title>,&#8221; <source>Journal of the American Academy of Dermatology</source><volume>93</volume> (<year>2025</year>): <fpage>210</fpage>&#8211;<lpage>212</lpage>, <pub-id pub-id-type="doi">10.1016/j.jaad.2025.02.090</pub-id>.<pub-id pub-id-type="pmid">40090588</pub-id></mixed-citation></ref><ref id="exd70134-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="exd70134-cit-0017"><string-name name-style="western"><given-names>Y.</given-names><surname>Hamada</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Quartagno</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Law</surname></string-name>, et&#160;al., &#8220;<article-title>Association of Diabetes, Smoking, and Alcohol Use With Subclinical&#8208;To&#8208;Symptomatic Spectrum of Tuberculosis in 16 Countries: An Individual Participant Data Meta&#8208;Analysis of National Tuberculosis Prevalence Surveys</article-title>,&#8221; <source>EClinicalMedicine</source><volume>63</volume> (<year>2023</year>): <elocation-id>102191</elocation-id>.<pub-id pub-id-type="pmid">37680950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.102191</pub-id><pub-id pub-id-type="pmcid">PMC10480554</pub-id></mixed-citation></ref><ref id="exd70134-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="exd70134-cit-0018"><string-name name-style="western"><given-names>A.</given-names><surname>Grifoni</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Alonzi</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Alter</surname></string-name>, et&#160;al., &#8220;<article-title>Impact of Aging on Immunity in the Context of COVID&#8208;19, HIV, and Tuberculosis</article-title>,&#8221; <source>Frontiers in Immunology</source><volume>14</volume> (<year>2023</year>): <elocation-id>1146704</elocation-id>.<pub-id pub-id-type="pmid">37292210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1146704</pub-id><pub-id pub-id-type="pmcid">PMC10246744</pub-id></mixed-citation></ref><ref id="exd70134-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="exd70134-cit-0019"><string-name name-style="western"><given-names>J.</given-names><surname>Wessels</surname></string-name>, <string-name name-style="western"><given-names>C. M.</given-names><surname>Walsh</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Nel</surname></string-name>, &#8220;<article-title>Smoking Habits and Alcohol Use of Patients With Tuberculosis at Standerton Tuberculosis Specialised Hospital, Mpumalanga, South Africa</article-title>,&#8221; <source>Health SA</source><volume>24</volume> (<year>2019</year>): <elocation-id>1146</elocation-id>.<pub-id pub-id-type="pmid">31934425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4102/hsag.v24i0.1146</pub-id><pub-id pub-id-type="pmcid">PMC6917417</pub-id></mixed-citation></ref><ref id="exd70134-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="exd70134-cit-0020"><string-name name-style="western"><given-names>C.</given-names><surname>Feldman</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>Theron</surname></string-name>, <string-name name-style="western"><given-names>M. C.</given-names><surname>Cholo</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Anderson</surname></string-name>, &#8220;<article-title>Cigarette Smoking as a Risk Factor for Tuberculosis in Adults: Epidemiology and Aspects of Disease Pathogenesis</article-title>,&#8221; <source>Pathogens</source><volume>13</volume> (<year>2024</year>): <fpage>13</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pathogens13020151</pub-id><pub-id pub-id-type="pmcid">PMC10892798</pub-id><pub-id pub-id-type="pmid">38392889</pub-id></mixed-citation></ref><ref id="exd70134-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="exd70134-cit-0021"><string-name name-style="western"><given-names>D. R.</given-names><surname>Silva</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Munoz&#8208;Torrico</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Duarte</surname></string-name>, et&#160;al., &#8220;<article-title>Risk Factors for Tuberculosis: Diabetes, Smoking, Alcohol Use, and the Use of Other Drugs</article-title>,&#8221; <source>Jornal Brasileiro de Pneumologia</source><volume>44</volume> (<year>2018</year>): <fpage>145</fpage>&#8211;<lpage>152</lpage>.<pub-id pub-id-type="pmid">29791552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/S1806-37562017000000443</pub-id><pub-id pub-id-type="pmcid">PMC6044656</pub-id></mixed-citation></ref><ref id="exd70134-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="exd70134-cit-0022"><string-name name-style="western"><given-names>G. W.</given-names><surname>Wigger</surname></string-name>, <string-name name-style="western"><given-names>T. C.</given-names><surname>Bouton</surname></string-name>, <string-name name-style="western"><given-names>K. R.</given-names><surname>Jacobson</surname></string-name>, <string-name name-style="western"><given-names>S. C.</given-names><surname>Auld</surname></string-name>, <string-name name-style="western"><given-names>S. M.</given-names><surname>Yeligar</surname></string-name>, and <string-name name-style="western"><given-names>B. S.</given-names><surname>Staitieh</surname></string-name>, &#8220;<article-title>The Impact of Alcohol Use Disorder on Tuberculosis: A Review of the Epidemiology and Potential Immunologic Mechanisms</article-title>,&#8221; <source>Frontiers in Immunology</source><volume>13</volume> (<year>2022</year>): <elocation-id>864817</elocation-id>.<pub-id pub-id-type="pmid">35432348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.864817</pub-id><pub-id pub-id-type="pmcid">PMC9009367</pub-id></mixed-citation></ref><ref id="exd70134-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="exd70134-cit-0023"><string-name name-style="western"><given-names>C.</given-names><surname>Naslund&#8208;Koch</surname></string-name> and <string-name name-style="western"><given-names>L.</given-names><surname>Skov</surname></string-name>, &#8220;<article-title>Shedding Light on the Smoke: Unravelling the Impact of Smoking Cessation on Psoriasis Development</article-title>,&#8221; <source>British Journal of Dermatology</source><volume>191</volume> (<year>2024</year>): <fpage>157</fpage>&#8211;<lpage>158</lpage>.<pub-id pub-id-type="pmid">38616721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bjd/ljae163</pub-id></mixed-citation></ref><ref id="exd70134-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="exd70134-cit-0024"><string-name name-style="western"><given-names>J.</given-names><surname>Choi</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Han</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Min</surname></string-name>, et&#160;al., &#8220;<article-title>Dose&#8208;Response Analysis Between Alcohol Consumption and Psoriasis: A Systematic Review and Meta&#8208;Analysis</article-title>,&#8221; <source>Journal der Deutschen Dermatologischen Gesellschaft</source><volume>22</volume> (<year>2024</year>): <fpage>641</fpage>&#8211;<lpage>652</lpage>.<pub-id pub-id-type="pmid">38679782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ddg.15380</pub-id></mixed-citation></ref><ref id="exd70134-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="exd70134-cit-0025"><string-name name-style="western"><given-names>N.</given-names><surname>Manzanares</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Vilarrasa</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Lopez</surname></string-name>, et&#160;al., &#8220;<article-title>No Tuberculosis Reactivations in Psoriasis Patients Initiating New Generation Biologics Despite Untreated Latent Tuberculosis Infection: Multicenter Case Series of 35 Patients</article-title>,&#8221; <source>Journal of the European Academy of Dermatology and Venereology</source><volume>38</volume> (<year>2024</year>): <fpage>e26</fpage>&#8211;<lpage>e28</lpage>.<pub-id pub-id-type="pmid">37561934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.19406</pub-id></mixed-citation></ref><ref id="exd70134-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="exd70134-cit-0026"><string-name name-style="western"><given-names>M.</given-names><surname>Megna</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Potestio</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Ruggiero</surname></string-name>, et&#160;al., &#8220;<article-title>JAK Inhibitors in Psoriatic Disease</article-title>,&#8221; <source>Clinical, Cosmetic and Investigational Dermatology</source><volume>16</volume> (<year>2023</year>): <fpage>3129</fpage>&#8211;<lpage>3145</lpage>.<pub-id pub-id-type="pmid">37927384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CCID.S433367</pub-id><pub-id pub-id-type="pmcid">PMC10625379</pub-id></mixed-citation></ref><ref id="exd70134-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="exd70134-cit-0027"><string-name name-style="western"><given-names>A.</given-names><surname>Kerschbaumer</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Smolen</surname></string-name>, <string-name name-style="western"><given-names>R. J. O.</given-names><surname>Ferreira</surname></string-name>, et&#160;al., &#8220;<article-title>Efficacy and Safety of Pharmacological Treatment of Psoriatic Arthritis: A Systematic Literature Research Informing the 2023 Update of the EULAR Recommendations for the Management of Psoriatic Arthritis</article-title>,&#8221; <source>Annals of the Rheumatic Diseases</source><volume>83</volume> (<year>2024</year>): <fpage>760</fpage>&#8211;<lpage>774</lpage>.<pub-id pub-id-type="pmid">38503473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ard-2024-225534</pub-id><pub-id pub-id-type="pmcid">PMC11103324</pub-id></mixed-citation></ref><ref id="exd70134-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="exd70134-cit-0028"><string-name name-style="western"><given-names>K. L.</given-names><surname>Winthrop</surname></string-name>, <string-name name-style="western"><given-names>S. H.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Gul</surname></string-name>, et&#160;al., &#8220;<article-title>Tuberculosis and Other Opportunistic Infections in Tofacitinib&#8208;Treated Patients With Rheumatoid Arthritis</article-title>,&#8221; <source>Annals of the Rheumatic Diseases</source><volume>75</volume> (<year>2016</year>): <fpage>1133</fpage>&#8211;<lpage>1138</lpage>.<pub-id pub-id-type="pmid">26318385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2015-207319</pub-id><pub-id pub-id-type="pmcid">PMC4893093</pub-id></mixed-citation></ref><ref id="exd70134-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="exd70134-cit-0029"><string-name name-style="western"><given-names>J. A.</given-names><surname>Singh</surname></string-name>, <string-name name-style="western"><given-names>K. G.</given-names><surname>Saag</surname></string-name>, <string-name name-style="western"><given-names>S. L.</given-names><surname>Bridges</surname>, <suffix>Jr.</suffix></string-name>, et&#160;al., &#8220;<article-title>2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis</article-title>,&#8221; <source>Arthritis &amp; Rhematology</source><volume>68</volume> (<year>2016</year>): <fpage>1</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.39480</pub-id><pub-id pub-id-type="pmid">26545940</pub-id></mixed-citation></ref><ref id="exd70134-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="exd70134-cit-0030"><string-name name-style="western"><given-names>T.</given-names><surname>Torres</surname></string-name>, <string-name name-style="western"><given-names>N. C.</given-names><surname>Brembilla</surname></string-name>, <string-name name-style="western"><given-names>R. G.</given-names><surname>Langley</surname></string-name>, et&#160;al., &#8220;<article-title>Treatment of Psoriasis With Biologic and Non&#8208;Biologic Targeted Therapies in Patients With Latent Tuberculosis Infection or at Risk for Tuberculosis Disease Progression: Recommendations From a SPIN&#8208;FRT Expert Consensus</article-title>,&#8221; <source>Journal of the European Academy of Dermatology and Venereology</source><volume>39</volume> (<year>2025</year>): <fpage>52</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="pmid">39149807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.20287</pub-id></mixed-citation></ref><ref id="exd70134-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="exd70134-cit-0031"><string-name name-style="western"><given-names>P.</given-names><surname>Rodriguez&#8208;Jimenez</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Mir&#8208;Viladrich</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Chicharro</surname></string-name>, et&#160;al., &#8220;<article-title>Prevention and Treatment of Tuberculosis Infection in Candidates for Biologic Therapy: A Multidisciplinary Consensus Statement Adapted to the Dermatology Patient</article-title>,&#8221; <source>Actas Dermo&#8208;Sifiliogr&#225;ficas (English Edition)</source><volume>109</volume> (<year>2018</year>): <fpage>584</fpage>&#8211;<lpage>601</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ad.2018.03.013</pub-id><pub-id pub-id-type="pmid">29871738</pub-id></mixed-citation></ref><ref id="exd70134-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="exd70134-cit-0032"><string-name name-style="western"><given-names>F.</given-names><surname>Cantini</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Prignano</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Goletti</surname></string-name>, &#8220;<article-title>Restarting Biologics and Management of Patients With Flares of Inflammatory Rheumatic Disorders or Psoriasis During Active Tuberculosis Treatment</article-title>,&#8221; <source>Journal of Rheumatology. Supplement</source><volume>91</volume> (<year>2014</year>): <fpage>78</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">24789004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3899/jrheum.140106</pub-id></mixed-citation></ref><ref id="exd70134-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="exd70134-cit-0033"><string-name name-style="western"><given-names>D. K.</given-names><surname>Jha</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Kakadiya</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Sharma</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Naidu</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>De</surname></string-name>, and <string-name name-style="western"><given-names>V.</given-names><surname>Sharma</surname></string-name>, &#8220;<article-title>Assessment and Management for Latent Tuberculosis Before Advanced Therapies for Immune&#8208;Mediated Inflammatory Diseases: A Comprehensive Review</article-title>,&#8221; <source>Autoimmunity Reviews</source><volume>24</volume> (<year>2025</year>): <elocation-id>103758</elocation-id>.<pub-id pub-id-type="pmid">39870187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2025.103758</pub-id></mixed-citation></ref><ref id="exd70134-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="exd70134-cit-0034"><string-name name-style="western"><given-names>T.</given-names><surname>Torres</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Chiricozzi</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Puig</surname></string-name>, et&#160;al., &#8220;<article-title>Treatment of Psoriasis Patients With Latent Tuberculosis Using IL&#8208;17 and IL&#8208;23 Inhibitors: A Retrospective, Multinational, Multicentre Study</article-title>,&#8221; <source>American Journal of Clinical Dermatology</source><volume>25</volume> (<year>2024</year>): <fpage>333</fpage>&#8211;<lpage>342</lpage>.<pub-id pub-id-type="pmid">38265746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40257-024-00845-4</pub-id><pub-id pub-id-type="pmcid">PMC10867072</pub-id></mixed-citation></ref><ref id="exd70134-bib-0035"><label>35</label><mixed-citation publication-type="book" id="exd70134-cit-0035"><source>Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management</source> (<publisher-name>WHO</publisher-name>, <year>2018</year>).<pub-id pub-id-type="pmid">30277688</pub-id></mixed-citation></ref><ref id="exd70134-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="exd70134-cit-0036"><string-name name-style="western"><given-names>A.</given-names><surname>Thatiparthi</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Martin</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Egeberg</surname></string-name>, and <string-name name-style="western"><given-names>J. J.</given-names><surname>Wu</surname></string-name>, &#8220;<article-title>Biologic Treatment Algorithms for Moderate&#8208;To&#8208;Severe Psoriasis With Comorbid Conditions and Special Populations: A Review</article-title>,&#8221; <source>American Journal of Clinical Dermatology</source><volume>22</volume> (<year>2021</year>): <fpage>425</fpage>&#8211;<lpage>442</lpage>.<pub-id pub-id-type="pmid">33861409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40257-021-00603-w</pub-id><pub-id pub-id-type="pmcid">PMC8051287</pub-id></mixed-citation></ref><ref id="exd70134-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="exd70134-cit-0037"><string-name name-style="western"><given-names>A.</given-names><surname>Nast</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Smith</surname></string-name>, <string-name name-style="western"><given-names>P. I.</given-names><surname>Spuls</surname></string-name>, et&#160;al., &#8220;<article-title>EuroGuiDerm Guideline on the Systemic Treatment of Psoriasis Vulgaris &#8211; Part 2: Specific Clinical and Comorbid Situations</article-title>,&#8221; <source>Journal of the European Academy of Dermatology and Venereology</source><volume>35</volume> (<year>2021</year>): <fpage>281</fpage>&#8211;<lpage>317</lpage>.<pub-id pub-id-type="pmid">33547728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.16926</pub-id></mixed-citation></ref><ref id="exd70134-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="exd70134-cit-0038"><string-name name-style="western"><given-names>C. R.</given-names><surname>Holroyd</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Seth</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Bukhari</surname></string-name>, et&#160;al., &#8220;<article-title>The British Society for Rheumatology Biologic DMARD Safety Guidelines in Inflammatory Arthritis</article-title>,&#8221; <source>Rheumatology (Oxford)</source><volume>58</volume> (<year>2019</year>): <fpage>e3</fpage>&#8211;<lpage>e42</lpage>.<pub-id pub-id-type="pmid">30137552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/key208</pub-id></mixed-citation></ref><ref id="exd70134-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="exd70134-cit-0039"><string-name name-style="western"><given-names>F.</given-names><surname>Cantini</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Nannini</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Niccoli</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Petrone</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Ippolito</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Goletti</surname></string-name>, &#8220;<article-title>Risk of Tuberculosis Reactivation in Patients With Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non&#8208;Anti&#8208;TNF&#8208;Targeted Biologics</article-title>,&#8221; <source>Mediators of Inflammation</source><volume>2017</volume> (<year>2017</year>): <elocation-id>8909834</elocation-id>.<pub-id pub-id-type="pmid">28659665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2017/8909834</pub-id><pub-id pub-id-type="pmcid">PMC5474286</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>